Novel N-hydroxamic acid hydrazide inhibitors of TNF-α synthesis

Abstract

Two patent applications claim novel N-hydroxamic acid hydrazide inhibitors of TNF-α synthesis, that act via inhibition of the TNF-α-converting enzyme (TACE or ADAM-17). The hydrazides are claimed to be useful in the treatment of inflammatory diseases such as rheumatoid arthritis. The claimed sulphonylhydrazide and cyclic hydrazide derivatives both display comparable in vitro potency to Roche’s clinical development lead Ro 32-7315.

• ADAM-17
• rheumatoid arthritis
• TACE
• TNF-α
• TNF synthesis inhibitor